669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection

Benzer Materyaller

• 670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
  Yazar:: Hau, Heidi, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
  Yazar:: Khanna, Sahil, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• 1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
  Yazar:: Mische, Sarah, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
  Yazar:: Orenstein, Robert, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• 30. Antimicrobial Resistance Genes Are Reduced Following Administration of Investigational Microbiota-based Therapeutic RBX7455 to Individuals with Recurrent clostrioides Difficile Infection
  Yazar:: Walsh, Dana, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)